参考文献
1: Issa D, Wattacheril J, Sanyal AJ. Treatment options for nonalcoholic steatohepatitis - a safety evaluation. Expert Opin Drug Saf. 2017 Aug;16(8):903-913. doi: 10.1080/14740338.2017.1343299. Epub 2017 Jul 6. Review. PubMed PMID: 28641031.
2: Kim W. [Treatment Options in Non-alcoholic Fatty Liver Disease]. Korean J Gastroenterol. 2017 Jun 25;69(6):353-358. doi: 10.4166/kjg.2017.69.6.353. Review. Korean. PubMed PMID: 28637104.
3: Perazzo H, Dufour JF. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int. 2017 May;37(5):634-647. doi: 10.1111/liv.13270. Epub 2016 Nov 7. Review. PubMed PMID: 27727520.
4: Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017 Jan;66(1):180-190. doi: 10.1136/gutjnl-2016-312431. Epub 2016 Sep 19. Review. PubMed PMID: 27646933.
5: Townsend SA, Newsome PN. Non-alcoholic fatty liver disease in 2016. Br Med Bull. 2016 Sep;119(1):143-56. doi: 10.1093/bmb/ldw031. Epub 2016 Aug 19. Review. PubMed PMID: 27543499.
6: Brodosi L, Marchignoli F, Petroni ML, Marchesini G. NASH: A glance at the landscape of pharmacological treatment. Ann Hepatol. 2016 Sep-Oct;15(5):673-81. doi: 10.5604/16652681.1212318. Review. PubMed PMID: 27493105.
7: Ratziu V. Novel Pharmacotherapy Options for NASH. Dig Dis Sci. 2016 May;61(5):1398-405. doi: 10.1007/s10620-016-4128-z. Epub 2016 Mar 22. Review. PubMed PMID: 27003143.
8: Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol. 2016 Mar-Apr;22(2):91-105. doi: 10.4103/1319-3767.178527. Review. PubMed PMID: 26997214; PubMed Central PMCID: PMC4817303.
9: Liu ZM, Hu M, Chan P, Tomlinson B. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opin Investig Drugs. 2015 May;24(5):611-21. doi: 10.1517/13543784.2015.1006359. Epub 2015 Jan 21. Review. PubMed PMID: 25604802.
10: Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs. 2014 Oct;23(10):1441-8. doi: 10.1517/13543784.2014.954034. Epub 2014 Aug 28. Review. PubMed PMID: 25164277.
11: Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014 Mar;15(4):493-503. doi: 10.1517/14656566.2014.876992. Epub 2014 Jan 16. Review. PubMed PMID: 24428677.
